Yair Herishanu

Tel Aviv, TA, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 124 publications

Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study.

Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study.

Journal: Leukemia & lymphoma
Published: August 09, 2026

Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study.

Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study.

Journal: American journal of hematology
Published: April 09, 2026

Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.

Eligibility Matched Benchmarking of Second-Line Anti-CD19 Chimeric Antigen Receptor-T and Glofit-GemOx (STARGLO) Outcomes in Large B-Cell Lymphoma.

Journal: Transplantation and cellular therapy
Published: April 04, 2026

Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter's transformation: results from the phase II GIVeRS trial.

Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter's transformation: results from the phase II GIVeRS trial.

Journal: Haematologica
Published: February 19, 2026

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Journal: Blood
Published: October 22, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Journal: Blood
Published: October 22, 2025

Attenuated antibody responses to respiratory syncytial virus vaccination in hematologic malignancies: impact of anti-CD20 therapy.

Attenuated antibody responses to respiratory syncytial virus vaccination in hematologic malignancies: impact of anti-CD20 therapy.

Journal: Haematologica
Published: September 24, 2025

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.

Journal: Haematologica
Published: August 19, 2025

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Journal: Blood advances
Published: July 14, 2025

CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia.

CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia.

Journal: Journal of cellular and molecular medicine
Published: March 29, 2025

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.

International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations.

Journal: Blood
Published: January 17, 2025

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Journal: Leukemia
Published: December 03, 2024
Showing 1-12 of 124

Last Updated: 09/26/2026